bioAffinity Technologies (NASDAQ:BIAF) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of bioAffinity Technologies (NASDAQ:BIAF) from a sell rating to a hold rating in a report published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

bioAffinity Technologies Trading Up 3.3%

bioAffinity Technologies stock opened at $0.68 on Friday. The stock has a 50-day moving average price of $1.12 and a 200 day moving average price of $1.69. The company has a market capitalization of $3.23 million, a price-to-earnings ratio of -0.06 and a beta of -1.11. bioAffinity Technologies has a 52 week low of $0.61 and a 52 week high of $13.50. The company has a quick ratio of 1.34, a current ratio of 1.36 and a debt-to-equity ratio of 0.15.

bioAffinity Technologies (NASDAQ:BIAF) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($2.40) by $1.59. bioAffinity Technologies had a negative net margin of 280.53% and a negative return on equity of 285.75%. The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $1.48 million.

Institutional Trading of bioAffinity Technologies

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC acquired a new position in bioAffinity Technologies in the fourth quarter valued at approximately $36,000. Scientech Research LLC purchased a new stake in bioAffinity Technologies in the 3rd quarter worth approximately $49,000. Finally, J. Safra Sarasin Holding AG acquired a new stake in shares of bioAffinity Technologies during the 1st quarter worth approximately $164,000. 1.64% of the stock is owned by institutional investors and hedge funds.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.